Adult Ear Infection: Treatment, Types, Causes, Symptoms

retinal diseases :: Article Creator

Hawaiian Eye And Retina 2024: Neuro Op Mimics Of Thyroid Eye Disease

ConferencesHawaiian Eye and Retina

David Hutton of Ophthalmology Times talks with Andrew Lee, MD, about his presentation "Neuro op mimics of thyroid eye disease" at this year's Hawaiian Eye and Retina 2024 Meeting.

Video Transcript

Editor's note - This transcript has been edited for clarity.

David Hutton:

I'm David Hutton of Ophthalmology Times. Hawaiian Eye is taking place once again this year at the Grand Wailea Resort in Maui. Joining me today is Dr Andrew Lee, who is presenting, "Neuro op mimics of thyroid eye disease." Thank you so much for joining us today, Dr Lee. Tell us about this presentation.

Andrew G Lee, MD:

Yeah, so, thyroid eye disease, as you know, is a very common condition, and the most common cause of eye disease in people with thyroid disease is thyroid eye disease. It presents with a bulgey eye proptosis, lid retraction, lid lag, which is the lagging of the lid when they look down, and it can cause double vision or loss of vision. Unfortunately, there are other conditions that can mimic these exact same findings and aren't thyroid eye disease. And so the things that we're going to be talking about are, what are the differentiating and distinguishing features that suggest that it's a mimic of thyroid eye disease and not thyroid eye disease itself? And so we're going to be talking about some of the big red flags for it not being thyroid eye disease, like being strictly one eye only, unilateral, if it's the wrong muscle. So normally in thyroid diseases, the inferior, the medial, the lateral at last and the superior muscle, and if so, if it's the wrong muscle, that's always a big red flag and if you have proptosis, but no major treraction or lid retraction but no proptosis, or if the pattern of the motility deficit is abnormal for thyroid: These are the big red flags that it might be a mimic.

David Hutton:

Ultimately, what can knowing this mean for ophthalmologists and the patients they treat?

Andrew G Lee, MD:

So ophthalmologists need to know that common things are common and the most common presentation of thyroid eye disease is lid retraction, lid lag, proptosis, double vision, and if they have loss of vision from a compressive optic neuropathy, and if so, there's anything atypical about the pattern: wrong side, wrong muscle, wrong deviation, proptosis but no lid retraction, lid reaction but no proptosis, then they should do a scan, and an MRI should be performed. What we're looking for things like lymphoma, carotid cavernous fistula, orbital inflammatory pseudotumor, things that look like the thyroid superficially, clinically, but if there's something funny about it, the imaging studies should be able to answer the question, "is it really thyroid or not?" And ultimately, if the imaging study doesn't answer the question, some of those patients have to come to biopsy, and the biopsy is what shows okay, it's cancer or not cancer, or if it's thyroid disease.

The Interconnected Body: How The Eyes Reveal Signs Of Cardiovascular Disease

Normal Retina.

Multidisciplinary Digital Publishing Institute (MDPI)

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision.

In 1999, I defined regenerative medicine as the collection of interventions that restore tissues and organs damaged by disease, injured by trauma, or worn by time to normal function. I include a full spectrum of chemical, gene, and protein-based medicines, cell-based therapies, and biomechanical interventions that achieve that goal.

Our eyes are one of the most remarkable organs in our body, serving as the windows to our souls and providing a wealth of information about our overall health. Recent scientific research has demonstrated that the eyes can reveal signs of various diseases, including cardiovascular disease.

Cardiovascular disease is a severe and prevalent health condition worldwide that can lead to death if not detected early. Fortunately, our eyes can provide valuable insights into the disease. By closely examining the eyes, doctors can identify several indications of cardiovascular disease, and early detection can lead to timely intervention and better patient outcomes.

An Interbody Link

The human eyes are an incredible organ linked to different body parts through a complex network of veins, arteries, and nerves. These connections allow the eyes to provide valuable information about the body's overall health. For instance, the eyes can display symptoms of diseases affecting other parts of the body, making them an essential tool for diagnosis.

The eyes are connected to various body organs, such as the skin, joints, and gastrointestinal system. Through this interbody link, the eyes can show signs of diseases such as diabetes, high blood pressure, and cancer. For example, high blood pressure can cause changes to the blood vessels in the eyes, leading to blurry vision or even blindness. Similarly, diabetes can cause damage to the tiny blood vessels in the retina, leading to vision loss.

The Eyes as a Screening Tool

With advances in retinal imaging, it is now possible to detect diseases in other body parts by examining the eyes. This is because the eyes contain a wealth of information about the body's health. Retinal imaging can help to detect signs of diseases such as Alzheimer's, Parkinson's, and multiple sclerosis. It can also aid in early heart disease, stroke, and cancer detection.

Retinal imaging is an affordable and non-invasive method that captures accurate and detailed retina images - the thin layer of tissue at the back of the eye responsible for converting light into neural signals. These images can provide valuable information about the health of the eyes and the body.

Researchers are developing systems that can automatically scan retinal photos for signs of various diseases, including cardiovascular disease. Using machine learning algorithms, these systems can learn from vast datasets of retinal images with known disease outcomes and identify subtle patterns or abnormalities that may indicate disease.

Studies have shown that this approach has yielded promising results. If successful, it can significantly improve the efficiency and accuracy of retinal screening, leading to earlier disease detection and better patient outcomes, particularly in the case of cardiovascular diseases.

Seeing Your Heart Health

When it comes to the eyes, several signs may indicate the presence of cardiovascular disease. One of these symptoms is double vision or diplopia. This means a person sees two images of a single object instead of one. Double vision can occur in one or both eyes and be constant or intermittent. It may also be accompanied by other symptoms such as headaches, dizziness, and difficulty with balance and coordination.

Another indicator is a yellowish ring around the cornea, an arcus senilis. This ring is usually seen in older adults. Still, when present in younger people, it may suggest high cholesterol levels, which can increase the risk of heart disease.

A patient with hypertension

EyeNet Magazine by American Academy of Opthalmology

High blood pressure is another sign of cardiovascular disease, and it can cause damage to the blood vessels in the retina. This can result in changes such as narrowing or ballooning. Individuals with cholesterol deposits in or around their eyes are at an increased risk of stroke and heart attack. Moreover, high blood pressure can cause changes in the blood vessels in the retina, leading to the appearance of narrowed, thickened, or even ruptured blood vessels. These changes can be detected through an eye exam and may signal an increased risk of stroke or heart attack.

These diagnostic imaging scans showcase occlusions in arterial (2a) and venous (2b) systems, ... [+] represented by the black areas.

Retinal vein occlusion is an eye condition that affects the veins in the retina. This condition is often associated with vascular disease. It occurs when blood flow through the retinal veins is blocked, causing swelling and bleeding in the eye. Retinal vein occlusion is a severe manifestation of vascular disease. It can be an indicator of significant atherosclerosis in the body. Those with this condition are at a higher risk of developing other cardiovascular problems, such as heart attack or stroke.

It has been found that age-related macular degeneration (AMD), which is a common cause of vision loss for older adults, is linked to cardiovascular disease and stroke. A study by Mount Sinai revealed that patients with cardiovascular disease were three times more likely to suffer from a specific type of AMD, which indicates a close relationship between these two disorders.

Moreover, the appearance of small, yellowish deposits, called drusen, in the retina could also indicate cardiovascular disease. These deposits can cause impaired vision and are commonly seen in individuals with age-related macular degeneration, which has been associated with an increased risk of cardiovascular disease.

The Eye is a Diagnostic Dream

In summary, as the field of retinal imaging and artificial intelligence continues to advance, the eyes' diagnostic capabilities are expected to expand as a non-invasive and easily accessible tool for screening and early detection of a wide range of diseases, including cardiovascular diseases.

To learn more about the eye, read more stories at www.Williamhaseltine.Com

Iridex Launches New Iridex 532® And Iridex 577® Lasers In US Market Marking 35 Years Of Laser Innovation In Treating Retina Disorders & Glaucoma

IRIDEX Corporation

MOUNTAIN VIEW, Calif., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation, a global leader in innovative laser-based medical systems for the treatment of eye diseases, proudly announces the US launch of its next-generation platform Iridex 532® and Iridex 577® Lasers alongside its 35th anniversary celebration. The announcement was made ahead of their official showcase at the Hawaiian Eye and Retina 2024 Meeting from January 13-19, 2024.

Both lasers harness multiple treatment modes including continuous-wave and Iridex' patented MicroPulse® Technology and an intuitive touchscreen interface providing a wide range of clinical control options and features to optimize the treatment of retinal disorders and glaucoma.

David Bruce, President and CEO of Iridex Corporation, said, "The launch of the new Iridex 532 and Iridex 577 Lasers stands as a testament to our 35 year heritage of providing advanced laser solutions to ophthalmologists worldwide. These innovations mark a pivotal moment for us, blending modern technology with user-centric design to ensure optimized treatments for retinal disorders and glaucoma."

After previewing the new Iridex 577 nm Laser, Dr. Sam Mansour, Medical Director of the Virginia Retina Center, commented, "I was very pleased with the compact design and intuitive user interface. Its treatment-session recordings enhance therapeutic tracking from subsequent laser sessions, and the rapid maneuverability between console menus will undoubtedly improve patient flow. Having used Iridex laser systems for 30 years, I can attest to the highly dependable quality of their products."

Product Highlights:

Comprehensive Treatment Reports: Physicians can create detailed reports of treatment parameters for every procedure. These reports can be easily managed and downloaded to a USB drive.

Configurable Preset Filters: Customizable filters, allowing for simple program management and selection via the new preset management tool enabling customizable selections by procedure and by individual doctor.

Enhanced User Experience: The multi-functional single control knob ensures simplified console navigation. Additionally, the 7" high-resolution touchscreen display offers an interactive experience, allowing physicians to navigate seamlessly between options.

MicroPulse® Laser Applications: MicroPulse®, a laser delivery modality that adds fine control of photothermal effects in laser photocoagulation, is a tissue-sparing solution for the treatment of retinal diseases and glaucoma.

Story continues

About Iridex Corporation In 2024, Iridex Corporation celebrates its 35th anniversary as a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company's proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex's current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.Iridex.Com.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning clinical expectations and commercial trends, market adoption and expansion, demand for and utilization of the Company's products and results and expected sales volumes. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 20, 2023. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

Media ContactSteven Koufosskoufos@iridex.Com

Search This Blog

Otitis Media